Resmetirom Tablet Franchise in Ahmedabad

Lipid & Liver Care Tablet Supplier in Mumbai

NAFLD Medicine Distributor in Delhi

Metabolic Health Pharma Franchise in Bangalore

Resmetirom Tablet Stockist in Hyderabad
Lipid & Liver Care Tablet Manufacturer & Exporter in Chandigarh

Home/Products /resmetirom-100mg-tablet

Restripe 100 Tablet

Composition : Resmetirom (100mg) Tablet

Dosage Form : Tablet

Packaging Type : in a Bottle

Packaging : 30 Tablets

Price : ₹0/-

Restripe 100 Tablet contains Resmetirom 100mg, a high-strength therapy for lipid and liver health management. It works by reducing liver fat, improving lipid metabolism, and supporting overall liver function, making it ideal for patients with NAFLD and metabolic disorders.

Prescribers trust this tablet for its proven efficacy and patient-friendly profile, ensuring better adherence and consistent therapeutic outcomes. Patients benefit from improved liver health, optimized lipid levels, and enhanced long-term metabolic wellness.

For franchise partners, Restripe 100 Tablet is a high-demand product in the liver and metabolic care segment, offering strong sales potential and prescriber acceptance. Its advanced clinical profile makes it a profitable addition to specialty portfolios, enhancing market presence and business growth.

With rising incidence of NAFLD and metabolic disorders, Restripe 100 Tablet provides sustainable sales opportunities, helping partners build a strong foothold in the liver and lipid care segment.


Read More

About the Product

Restripe 100 Tablet contains Resmetirom 100mg, a high-strength therapy for lipid and liver health management. It works by reducing liver fat, improving lipid metabolism, and supporting overall liver function, making it ideal for patients with NAFLD and metabolic disorders.

Prescribers trust this tablet for its proven efficacy and patient-friendly profile, ensuring better adherence and consistent therapeutic outcomes. Patients benefit from improved liver health, optimized lipid levels, and enhanced long-term metabolic wellness.

For franchise partners, Restripe 100 Tablet is a high-demand product in the liver and metabolic care segment, offering strong sales potential and prescriber acceptance. Its advanced clinical profile makes it a profitable addition to specialty portfolios, enhancing market presence and business growth.

With rising incidence of NAFLD and metabolic disorders, Restripe 100 Tablet provides sustainable sales opportunities, helping partners build a strong foothold in the liver and lipid care segment.


Restripe 100 Tablet is indicated for the treatment of non-alcoholic steatohepatitis (NASH) and associated dyslipidemia in adults. It helps lower liver fat content, improve lipid metabolism, and reduce the risk of progression to advanced liver disease.

Restripe 100 Tablet is indicated for the treatment of non-alcoholic steatohepatitis (NASH) and associated dyslipidemia in adults. It helps lower liver fat content, improve lipid metabolism, and reduce the risk of progression to advanced liver disease.

Restripe 100 Tablet should be used strictly as prescribed by a healthcare professional. Patients with severe liver impairment or known hypersensitivity to Resmetirom should avoid this medication. Regular monitoring of liver function tests and lipid profiles is recommended during therapy. Inform your doctor about any concurrent medications or pre-existing conditions.

Store Restripe 100 Tablet in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children and do not use the medicine after the expiry date stated on the packaging.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation